Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis

Yi, Ren-liang; Chen, Baoxin; Duan, Peng; Zheng, Chengbin; Shen, Huanyu; Li, Qun; Chen, Yuan; Ou, Weilin; Zhang, Zhiheng

doi:10.1155/2016/4543861

Cited by 3 publications

(3 citation statements)

References 43 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For urological tumors, the treatment of advanced PCa is a challenge for professionals in the field, with first-rate morbidity, hormone resistance and a short patient overall survival making the current ADT-based combination of therapies seem overwhelming, with a negative impact on treatment. To this end, immunotherapy for PCa has evolved, with PD-1/PD-L1, and Sipuleucel-T, a DC-based autologous cellular immunotherapy, both approved by the FDA and used for treating patients with PCa [ 249 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , 257 , 258 ].…”

Section: Discussionmentioning

confidence: 99%

Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter

Wang

Liu

et al. 2022

IJMS

View full text Add to dashboard Cite

As the most common cancer of the genitourinary system, prostate cancer (PCa) is a global men′s health problem whose treatments are an urgent research issue. Treatment options for PCa include active surveillance (AS), surgery, endocrine therapy, chemotherapy, radiation therapy, immunotherapy, etc. However, as the cancer progresses, the effectiveness of treatment options gradually decreases, especially in metastatic castration-resistant prostate cancer (mCRPC), for which there are fewer therapeutic options and which have a shorter survival period and worse prognosis. For this reason, oncolytic viral therapy (PV), with its exceptional properties of selective tumor killing, relatively good safety in humans, and potential for transgenic delivery, has attracted increasing attention as a new form of anti-tumor strategy for PCa. There is growing evidence that OV not only kills tumor cells directly by lysis but can also activate anticancer immunity by acting on the tumor microenvironment (TME), thereby preventing tumor growth. In fact, evidence of the efficacy of this strategy has been observed since the late 19th century. However, subsequently, interest waned. The renewed interest in this therapy was due to advances in biotechnological methods and innovations at the end of the 20th century, which was also the beginning of PCa therapy with OV. Moreover, in combination with chemotherapy, radiotherapy, gene therapy or immunotherapy, OV viruses can have a wide range of applications and can provide an effective therapeutic result in the treatment of PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter

Wang

Liu

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…7 Despite a modest survival advantage demonstrated among men with mCRPC, uptake has been poor due to cost, complexity of administration and lack of immediate PSA decline, with no significant reduction of prostate-specific antigen level ⩾50% (PSA50 response) or improvement in progression-free survival. 8 There may be more effective means of targeting TAAs and TSAs, which could offer greater clinical benefit. Prostate-specific membrane antigen (PSMA) is a TAA that is highly expressed in mCRPC and has been validated as an effective target for treatment, with radionuclide therapy targeting PSMA shown to prolong progressionfree survival and overall survival in the TheraP and VISION trials.…”

Section: Introductionmentioning

confidence: 99%

The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review

Martin

Dorff

2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

The lack of success in prostate cancer from immune checkpoint inhibitors, which is likely multifactorial, has led to the development and investigation of a number of other novel immunotherapeutic techniques, including antibody–drug conjugates, T-cell redirected bispecific therapies, cancer vaccines and chimeric antigen receptor T-cell therapies. Prostate-specific membrane antigen (PSMA) is a tumour-associated antigen (TAA) that is highly expressed in metastatic prostate cancer and has been validated as an effective target for radionuclide treatment. But while PSMA has thus far been the ‘front runner’ target for these novel immunotherapeutic techniques, it may not be the ideal target for immunotherapy and there are other potential targetable TAAs that will require further exploration. This review will focus on these various PSMA-directed therapies, as well as other potential targets for immunotherapy beyond PSMA.

show abstract